Development and validation of an individualized immune prognostic model in stage I–III lung squamous cell carcinoma

Lung squamous cell carcinoma (LUSC) possesses a poor prognosis even for stages I–III resected patients. Reliable prognostic biomarkers that can stratify and predict clinical outcomes for stage I–III resected LUSC patients are urgently needed. Based on gene expression of LUSC tissue samples from five...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Qi-Fan, Wu, Di, Wang, Jian, Ba, Li, Tian, Chen, Liu, Yu-Ting, Hu, Yue, Liu, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209222/
https://www.ncbi.nlm.nih.gov/pubmed/34135424
http://dx.doi.org/10.1038/s41598-021-92115-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209222/
https://www.ncbi.nlm.nih.gov/pubmed/34135424
http://dx.doi.org/10.1038/s41598-021-92115-0

Ejemplares similares